Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01952886 | Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Sep 22, 2014 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | withdrawn | N/A | 0 | Duke UniversityOTHER | 0 | May 19, 2014 | clinicaltrials |
| NCT01778088 | Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma | withdrawn | Phase 2 | 0 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Feb 25, 2014 | clinicaltrials |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Jan 14, 2014 | clinicaltrials |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)(CLARITY-1) | withdrawn | Phase 2 | 0 | Sophiris Bio CorpINDUSTRY | 0 | Dec 3, 2012 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00985036 | Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients | withdrawn | — | 0 | Marquette General Health SystemOTHER | 1 | Apr 24, 2012 | clinicaltrials |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Dec 20, 2011 | clinicaltrials |
| NCT00469534 | Minimized Time to Beam in Patients With High Grade Gliomas | withdrawn | N/A | 0 | Alberta Health servicesOTHER | 0 | Sep 22, 2011 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | withdrawn | Phase 1 | 30 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | May 20, 2009 | clinicaltrials |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | withdrawn | Phase 3 | 323 | Xenova BiomedixINDUSTRY | 2 | Jan 7, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Sep 22, 2014source: clinicaltrials